(Q39250141)

English

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine (English)

1 reference

Europe PubMed Central

10 September 2017

10

object named as

Jaap Goudsmit

1 reference

Europe PubMed Central

10 September 2017

Hanneke Schuitemaker

12

object named as

Hanneke Schuitemaker

1 reference

Europe PubMed Central

10 September 2017

author name string

Barbara P Sanders

1

1 reference

Europe PubMed Central

10 September 2017

Diana Edo-Matas

2

1 reference

Europe PubMed Central

10 September 2017

Jerome H H V Custers

3

1 reference

Europe PubMed Central

10 September 2017

Martin H Koldijk

4

1 reference

Europe PubMed Central

10 September 2017

Vincent Klaren

5

1 reference

Europe PubMed Central

10 September 2017

Marije Turk

6

1 reference

Europe PubMed Central

10 September 2017

Alfred Luitjens

7

1 reference

Europe PubMed Central

10 September 2017

Wilfried A M Bakker

8

1 reference

Europe PubMed Central

10 September 2017

Fons Uytdehaag

9

1 reference

Europe PubMed Central

10 September 2017

John A Lewis

11

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

30 October 2012

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

31

1 reference

Europe PubMed Central

10 September 2017

850-856

1 reference

Europe PubMed Central

10 September 2017

5

1 reference

Europe PubMed Central

10 September 2017

Polio endgame. Polio: The final assault?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Properties and behavior of orally administered attenuated poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

World wide experience with inactivated poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Role of injectable and oral polio vaccines in polio eradication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

IMMUNITY TO POLIOMYELITIS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

From emergence to eradication: the epidemiology of poliomyelitis deconstructed

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

A sensitive cell-based assay for the detection of residual infectious West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Inactivated poliovirus vaccine: current production methods and new developments

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Production of poliovirus vaccines: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Polio eradication: the OPV paradox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Fractional doses of inactivated poliovirus vaccine in Oman

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Technology transfer of Sabin-IPV to new developing country markets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Protein-free culture of Vero cells: a substrate for replication of human pathogenic viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

The D-antigen content in poliovaccine as a measure of potency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.070

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.10.070

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39250141&oldid=1815898472"